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The observed increase in incidence of allergic disease in many regions over the past 3 decades has intensified
interest in understanding the epidemiology of severe allergic reactions. We discuss the issues in collecting and
interpreting these data and highlight current deficiencies in the current methods of data gathering.
Recent findings
Anaphylaxis, as measured by hospital admission rates, is not uncommon and has increased in the United
Kingdom, the United States, Canada, and Australia over the last 10–20 years. All large datasets are
hampered by a large proportion of uncoded, ‘unspecified’ causes of anaphylaxis. Fatal anaphylaxis remains
a rare event, but appears to be increasing for medication in Australia, Canada, and the United States. The
rate of fatal food anaphylaxis is stable in the United Kingdom and the United States, but has increased in
Australia. The age distribution for fatal food anaphylaxis is different to other causes, with data suggesting an
age-related predisposition to fatal outcomes in teenagers and adults to the fourth decade of life.
Summary
The increasing rates of food and medication allergy (the latter exacerbated by an ageing population) has
significant implications for future fatality trends. An improved ability to accurately gather and analyse
population-level anaphylaxis data in a harmonized fashion is required, so as to ultimately minimize risk
and improve management.
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Curr Opin Allergy Clin Immunol 2016, 16:441–450INTRODUCTION
Anaphylaxis is a termusedwidely to describe a severe
allergic reaction; however, there is no single defi-
nition agreed worldwide [1]. There has been signifi-
cant interest in the epidemiology of anaphylaxis,
perhapsdrivenby trendsof increasing allergic disease
observed in much of the developed world over the
past 3 decades. Measurement of population-based
patterns and causes of severe allergic reactionsmight
serve several purposes, including estimating the
regional burden of disease, identifying trends in
causal/triggering agents, tracking trends over time,
and in findingassociationswhichmayhelp topredict
or prevent severe disease or death. In this review, we
aim to outline how studying the epidemiology of
anaphylaxis might assist in the prevention of
anaphylaxis and anaphylaxis-related fatalities at an
individual and population-based level.DOI:10.1097/ACI.0000000000000305
This is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial License 4.0, where it is permiss-
ible to download, share, remix, transform, and buildup the work provided it
is properly cited. The work cannot be used commercially.UNDERSTANDING ANAPHYLAXIS
Understanding the pathophysiology of anaphylaxis
is crucial to predicting risk and interpretinght © 2016 Wolters Kluwe
rs Kluwer Health, Inc. All rights reseepidemiological associations. However, human data
are limited, and performing allergen challenges
under medical supervision to investigate mechan-
isms raises significant ethical and safety concerns.
Where such challenges have been performed, indi-
viduals with prior severe reactions may be excludedr Health, Inc. All rights reserved.
rved. www.co-allergy.com
KEY POINTS
 Anaphylaxis is increasing but fatal anaphylaxis
remains rare.
 Medications appear to be the most common cause of
anaphylaxis admissions and fatalities in the United
Kingdom, the United States, and Australia.
 Triggers such as medications, foods, and insect venoms
are associated with specific demographic patterns and
clinical presentations.
 Large data sets are hindered by lack of robust utilized
coding systems, with underreporting, miscoding, and
many cases of ‘unspecified’ triggers in admissions and
fatality registers.
Genetics and epidemiologyand the challenges themselves are designed (through
dose limitation) to avoid severe reactions, and are
therefore less likely to provide a valid picture of the
whole population of individuals at risk from severe
reactions. Some investigators have sought to capture
blood/bio samples formechanistic studies from indi-
viduals presenting to the emergency departments
during or immediately following anaphylaxis, but
these are prone to difficulties in defining the circum-
stances prior to arrival in the hospital and lack ‘base-
line’ samples to allow detailed assessment of
inflammatory mediators. Unfortunately, animal
models of mediators and mechanisms of anaphy-
laxis, particularly food-induced anaphylaxis, cannot
be extrapolated to humans (Table 1) [2–4,5
&
,6–14].DEFINING ANAPHYLAXIS AND SEVERE
ANAPHYLAXIS: WHY IS IT IMPORTANT?
Anaphylaxis is most commonly accepted to be a
potentially life-threatening systemic IgE-mediated
allergic reaction, with a spectrum of severity. To
accurately compare anaphylaxis data from different
regions and across centres within regions, it is useful
to have harmonized definitions of anaphylaxis.
However, ongoing regional variations in definition
persist (Table 2) [15–19], which are further con-
founded by confusion between what constitutes a
‘definition’ of anaphylaxis as opposed to a ‘descrip-
tion of symptoms’, that is, the clinical presentation
of anaphylaxis [20]. Indeed, the NIAID criteria for
anaphylaxis (which have gained widespread accept-
ance) are not a definition per se, but were developed
to capture at least 95% of cases [19].
In terms of accurately defining anaphylaxis, we
are faced with a number of important challenges.
Anaphylaxis is typically defined as a generalized
reaction; however, at least in the United Kingdom Copyright © 2016 Wolters Kluwer 
442 www.co-allergy.comand Australia, we have found that coroner’s reports
of fatal anaphylaxis (particularly to food) often
describe only symptoms localized to the throat
and lower airways before collapse and death (Pum-
phrey R, personal communication). Severe anaphy-
laxis may, therefore, initially present without
significant systemic symptoms. Not all episodes of
anaphylaxis necessarily result in a life-threatening
situation. Many individuals experiencing anaphy-
laxis will exhibit symptom resolution without
receiving appropriate treatment. For example, in a
prospective survey of teenagers attending the UK
allergy clinics, 245 of 969 had at least one episode of
anaphylaxis (according to NIAID criteria) in the
previous year; only 41 (17%) had used or been
administered epinephrine (adrenaline), despite all
being prescribed an autoinjector device. Thus, over
80% of teenagers in this cohort recovered
spontaneously from symptoms (including loss of
consciousness and difficulty in breathing) despite
not receiving epinephrine [21].
Arguably, our greatest challenge is the inability
to predict which patients, including those not pre-
viously known to be allergic, are most at risk of fatal
reactions [22
&&
]: can the literature assist us in
addressing this question? In this regard, it may be
helpful to focus on data related to ‘severe’ or life-
threatening anaphylaxis. However, what are the
determinants of severity? Is it the reaction itself or
the outcome of the reaction (which includes treat-
ment and any homeostatic compensation by the
allergic individual)? If an individual has anaphylaxis
(with both respiratory and cardiovascular symp-
toms) but promptly receives a single dose of intra-
muscular epinephrinewith good effect, is this still to
be considered a severe reaction?
One approach to narrowing anaphylaxis litera-
ture to more severe reactions is to only include cases
or reports which have case definitions requiring
hospitalization, on the assumption that only severe
cases need hospitalization. However, the decision to
admit an individual peri and postanaphylaxis may
depend not only on severity but also on local prac-
tice, individual healthcare professional, and patient
preference, which may, in turn, be influenced by
national guidelines. Arguably, near-fatal (requiring
intensive care) or fatal anaphylaxis may be a more
objective criterion of severity, but even here, many
factors will influence an admission to ICU.METHODOLOGICAL CHALLENGES IN
GATHERING AND USING POPULATION-
BASED ANAPHYLAXIS DATA
The use of different definitions of anaphylaxis and
severe anaphylaxis is just one challenge in terms ofHealth, Inc. All rights reserved.
Volume 16  Number 5  October 2016
Table 1. Significant differences in the literature with regard to the pathophysiology of anaphylaxis in murine models and the
mechanisms which may occur in humans
Murine models Humans References
1 :4 to 1 : 10 Neutrophil : lymphocyte ratio in
peripheral blood
2 : 1 to 1 : 1 [2]
Polymeric IgA (low serum levels) Immunoglobulins Monomeric IgA, two serotypes (IgA1
and IgA2), IgA1 abundant in serum
[3]
IgD, IgE, IgM IgD, IgE, IgM
IgG1, IgG2a, IgG2b, IgG3 IgG1, IgG2, IgG3, IgG4
Yes High-affinity IgE receptor (FceRI) on mast
cells and basophils
Yes [4]
No FceRI receptor on antigen-presenting cells Yes [4]
Yes IgE-dependent anaphylaxis Yes [4]
Yes IgG-dependent anaphylaxis No evidence for IgG-mediated
activation of human mast cells
[4,5&]
If present, likely to require very high
levels of antigen exposure
Very high: in murine models of peanut
allergy, dose/weight equivalent to a
human eating ﬃ1000 peanuts!
Allergen dose required through oral
exposure to cause anaphylaxis
Very low doses (mg), for example,
for peanut allergy, 10% of
individuals react to 1/70 of a
peanut
[6,7]
þ Sensitivity to histamine þþþþ [8,9]
Yes Anaphylaxis inhibited by H1-
antihistamines
Little clinical evidence for this.
Significant interspecies differences
exist in histamine receptor
pharmacology
[10,11,12]
Yes Basophils secrete platelet-activating
factor
Unclear [13,14]
Epidemiology of severe anaphylaxis Turner and Campbellderiving accurate anaphylaxis-related data. Differ-
ent methodologies are used in the literature; many
studies use self-report, which may overestimate the
true incidence by at least a factor of 10 [23]. Further
confusion may arise from variations in the use of
epidemiological terms. ‘Incidence’ is the number of
‘new’ cases occurring during a given time period in a
defined population, but many studies do not Copyright © 2016 Wolters Kluwe
Table 2. Current descriptions of anaphylaxis in the literature
EAACI [15] WAO [16] AAAAI/ACAAI [17]
A severe life-threatening
generalized or systemic
hypersensitivity reaction
An acute, potentially
fatal, multiorgan
system, allergic reaction
A serious life-threatening
generalized or systemic
hypersensitivity reaction
A serious allergic reaction
that is rapid in onset
and might cause death
An acute life-threatening
reaction with varied
mechanisms, clinical
presentations,
and severity that resu
from the sudden
release of mediators
from mast cells
and basophils
1528-4050 Copyright  2016 Wolters Kluwer Health, Inc. All rights resedistinguish between those having their first ‘ever’
episode, and others with previous anaphylaxis who
have a further anaphylaxis within the study period
(and are therefore, strictly speaking, not ‘new’
cases). Identification of cases by medical coding
systems, such as the ICD-10 system, is a common
methodological approach, but is prone to misclassi-
fication [23,24]. Retrospective data collection isr Health, Inc. All rights reserved.
ASCIA [18] NIAID [19]
systemic
lts
Anaphylaxis is a serious,
rapid-onset, allergic
reaction that may
cause death
Severe anaphylaxis is
characterized
by life-threatening
upper airway
obstruction, bronchospasm,
and/or hypotension
Anaphylaxis is a serious allergic
reaction that involves more
than one organ system
(e.g. skin, respiratory tract,
and/or gastrointestinal tract).
It can begin very rapidly, and
symptoms may be severe or
life-threatening
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Genetics and epidemiologysubject to incomplete reporting and recall bias.
Determining causality of anaphylaxis can be
challenging, particularly for reactions because of
medication/iatrogenic causes where medicolegal
concerns may affect reporting. Population-based
datasets are hampered by a large proportion of
uncoded, ‘unspecified’ causes of anaphylaxis
[25
&
,26,27
&
,28
&
]. Using stricter criteria to define
anaphylaxis (e.g. admission to intensive care)
reduces the number of cases, resulting in the same
challenges as those encountered in defining the
epidemiology of rare diseases, where very large
sample sizes are needed. It also has the likelihood
of skewing trigger data toward those where exposure
more commonly occurs in the hospital setting (such
as parenteral medications and contrasts agents) and
avoids severe cases where resolution occurs prior
to admission or results in a fatal outcome. Prospec-
tive collection of data, for example, through case
registries, is susceptible to similar issues regarding
the case definition, and in any event is unlikely to
include all cases [22
&&
].
Both anaphylaxis and fatal anaphylaxis com-
monly occur in the community and not in amedical
setting, so the circumstances of reaction and
description of symptoms are usually acquired from
nonmedical witnesses, further complicating categ-
orization. Using data from national death registries
and coroner’s reports to attribute cause and risk
factors is particularly problematic. In these instan-
ces, reports of symptoms are second-hand and
usually entered into coroner’s reports by the attend-
ing police official. Despite these shortcomings, data
registries and admission statistics remain a valuable
source of information which can provide insights
into at risk populations.WHAT DO WE KNOW ABOUT THE
EPIDEMIOLOGY OF SEVERE AND FATAL
ANAPHYLAXIS?
Fatal anaphylaxis is a rare occurrence. Estimates of
all-cause fatal anaphylaxis rates across the United
Kingdom [25
&
], the United States [26,27
&
], and Aus-
tralia [28
&
] over the past 2 decades range from 0.064
to 0.099 deaths per 100000 population per annum.
These rates are likely underestimates; however, the
true extent of misdiagnosis (such as acute severe
asthma and coronary infarct) and miscoding is
unknown. In a European anaphylaxis registry, only
5.5% of 1155 cases of severe anaphylaxis (laryngeal
oedema, bronchospasm, cyanosis, shock) involved
cardiorespiratory arrest [29]. In a subsequent paedi-
atric series from the same registry, 1.3% (26/1970)
cases involved life-threatening or fatal reactions
(five cases) [30
&
]. Copyright © 2016 Wolters Kluwer 
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reported to have increased in the United Kingdom
[25
&
], the United States [26], Canada [31], and
Australia [28
&
,32] over the past 2 decades; however,
an increase in all-cause fatality rates has only been
observed to date in Australia not the United King-
dom [25
&
], Canada (Ontario) [33], or the United
States [27
&
]. There was a seven-fold increase in the
UK hospitalizations for (all-cause) anaphylaxis from
1992 to 2012 (using government hospital datasets),
but no significant increase in fatalities over the same
time period (0.047 cases per 100000 per annum)
[25
&
]; a similar pattern has been reported in the
United States, with a modest annual increase in
all-cause hospitalizations between 1999 and 2009
of 2.2% but not fatalities [27
&
] (Table 3). In contrast,
an analysis of government hospital and death regis-
try datasets in Australia found an increase in both
hospitalizations and all-cause fatalities: admissions
increased almost four-fold (from 5.0 to 19.2 per
100000 population) between 1997 and 2013, with
a near doubling of fatalities (0.05 to 0.09 cases per
100000) over the same time period [28
&
]. In both the
United States and Australia, an increase in fatalities
because of medication-related anaphylaxis has been
reported [27
&
,28
&
]. This may, in part, reflect the
significant changes in prescription and intraopera-
tive/intervention practice such that at-risk individ-
uals are being exposed to more medications and
contrast agents.
Despite a worldwide focus on increasing food
allergy prevalence, the most frequent cause of
reported anaphylaxis-related deaths across Europe,
the United Kingdom, North America, and Australia
is medication [25
&
,26,27
&
,28
&
,29,30
&
,31]. Although
anaphylaxis to food is relatively common, fatal
food-triggered anaphylaxis is rare, with a reported
incidence of 1.35–2.71 per million person-years
[34]. The community focus on food allergy deaths
may, perhaps, be explained by the fact that in
children and young adults, food is the commonest
cause of severe anaphylaxis and these deaths
appear, at least superficially, to be the most pre-
ventable.FOOD ANAPHYLAXIS: POPULATIONS
AND INDIVIDUALS AT RISK
Children and young adults are proportionately over-
represented in food-related anaphylaxis admission
and fatalities. In the recent UK, US, and Australian
reports, young people under 19 years accounted for
4.8 to 15.8% of total fatalities, but only 0–3.4% of
those because of medication deaths and 0–1.6%
because of insect stings [25
&
,27
&
,28
&
]. The trend is
similar for admissions [25
&
,26,28
&
]. Australia has aHealth, Inc. All rights reserved.
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Table 3. Rates of hospitalization and fatalities (per 100000 population per annum) in the United Kingdom, the United States,
and Australia
The United Kingdom [25&] The United States [26,27&] Australia [28&,32]
1992 1998 2012 1999–2001 2008/2010 1997 2013
All-cause anaphylaxis
Hospitalizations 1.0 3.7 7.0 2.1 [26] 2.5 [26] 5.0 19.2
Fatalities 0.036 0.043 0.054 0.076 [26] 0.071 [26] 0.054 0.099
Anaphylaxis: food
Hospitalizations ND 1.2 2.4 0.61 [26] 0.83 [26] 1.6 8.9
Fatalities 0.010 0.012 0.012 0.003 [26] 0.004 [26] 0 0.009
0.005 [27&] 0.005 [27&]
Anaphylaxis: venom
Hospitalizations ND 0.09 0.46 ND ND ND ND
Fatalities 0.008 0.008 0.005 0.009 [26] 0.009 [26] 0.027 0.013
0.013 [27&] 0.010 [27&]
Anaphylaxis: medication
Hospitalizations ND 0.78 1.4 ND ND 1.4a 4.4
Fatalities 0.018 0.026 0.028 0.013 [26] 0.013 [26] 0.005 0.013
0.027 [27&] 0.051 [27&]
aData for 1999.
ND, no data available.
Epidemiology of severe anaphylaxis Turner and Campbellhigher rate of reported hospitalization because of
food anaphylaxis than elsewhere. However, the rate
of fatal food anaphylaxis is similar to the United
Kingdom (Table 3), and the rates for both regions are
almost double that reported for the United States. It
is interesting to speculate on the possible reasons for
this. Accurate reporting of admissions data may be
responsible for some differences. The prevalence of
food allergy appears higher per se in Australian
children [35] and could account for the differences
in admission rates, whereas perhaps lack of health
insurance is a disincentive for hospitalization
(rather than observation in emergency only) in
the United States. The differences in fatality rates
– if not because of incorrect attribution of causality
or miscoding – could be related to the differences in
themanagement of anaphylaxis between regions, or
possibly some underlying environmental protective
factor. This reinforces the need to establish
accurate national fatality registries for anaphy-
laxis-related deaths.
An emerging trend is the differences in risk for
fatal anaphylaxis by racial/ethnic origin: African-
American heritage was a significant risk factor for
fatal anaphylaxis because of food more than other
causes in the United States [27
&
], and has also been
associated with increased asthma mortality [36].
Whether this is because of inequalities to healthcare
or some predisposing factor is unclear. Within the
UK Fatal Anaphylaxis Registry, there is an excess Copyright © 2016 Wolters Kluwe
1528-4050 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseof deaths in male children because of cow’s milk
allergy in families of African, Middle East, or Far East
descent [20]. In a retrospective analysis, Buka et al.
[37] found a higher rate of severe anaphylaxis
in British children from families of South Asian
descent, an observation that was not because of
confounding by socioeconomic deprivation. Differ-
ences in the prevalence of peanut allergy have
been observed amongst infants where parents are
born in Asia versus Australia [38], although whether
this is associated with a more severe phenotype
is unclear.
Another emerging trend in fatal anaphylaxis
to food has been a change in the triggering allergen.
Traditionally, peanut has been thought to cause
most deaths; however, other allergens are now seen
to be as likely to cause severe reactions. In the
United Kingdom, cow’s milk is now the commonest
cause of fatal anaphylaxis in children [25
&
]; in
Australia, seafood is now the most common food
allergen implicated in fatal food-induced anaphy-
laxis, although peanut remains the most common
cause of death in children [28
&
].
A history of asthma is common in cases of fatal
food anaphylaxis [25
&
], more so than for other
causes of anaphylaxis [27
&
,28
&
]. However, in the
UK registry, many cases of fatal food anaphylaxis
did not have a history of increased symptoms or
reliever use (implying a change in asthma control)
prior to the fatal event. Around 50% of childrenr Health, Inc. All rights reserved.
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Genetics and epidemiology[39,40] and up to 25% of adults [29,41] with food
allergy have asthma, yet the vast majority will never
have a fatal allergic reaction; thus, the utility of
asthma as a predictor for fatal reactions is poor,
although this does not negate the value of improv-
ing asthma control as an important strategy in
risk management.VENOM
It is noteworthy that in North America and
the United Kingdom, the rates of severe anaphy-
laxis because of venom appear to be falling
[25
&
,26,27
&
,33]. Rates of venom fatalities in Australia
have been relatively stable since 1997, with no
significant decrease, but importantly have not
increased in line with food and medication-related
fatalities [28
&
]. The reason(s) for this are unknown,
but may be related to a falling population (’colony
collapse’) for bees that has occurred over the last
decade, something also now affecting the wasp
population in the United Kingdom [42]. Species-
specific data relating to the proportion of venom
anaphylaxis are lacking, and in any event, it can be
very difficult to identify the responsible insect for
most cases of insect-related anaphylaxis. The Cen-
tral European Registry reports wasp to be the most
common trigger for venom-induced anaphylaxis,
presumably on the basis of investigations performed
as a workup toward desensitization [43]; however,
in Australia Honey Bee, not wasp, accounts for the
majority of both venom immunotherapy prescrip-
tions [44] and fatalities because of insect anaphy-
laxis [28
&
]. Curiously, venom is the most common
cause of anaphylaxis in adults in the European
Registry [29], despite the fact that the national data-
sets report anaphylaxis to medications are more
common. This may be explained by the fact that
many allergic reactions because of medications are
not referred to allergy clinics, where healthcare
professionals would then submit these data to the
registry. In contrast, venom anaphylaxis is a com-
mon referral condition because of the widespread
availability of desensitization protocols which can
significantly reduce the adverse impact of the diag-
nosis on health-related quality of life [45,46].
In the United States [27
&
] and Australia [28
&
],
fatal anaphylaxis to insect venom is significantly
more common in middle-aged adult men. In the
United States, it is further associated with being
white, and in Australia, a rural setting, and upright
posture during anaphylaxis (e.g. being driven seated
in a car to a healthcare facility) were identified as
apparent significant risk factors for death from
insect allergy [28
&
]. Upright posture is likely to be
a risk factor for other anaphylaxis-related fatalities Copyright © 2016 Wolters Kluwer 
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deaths (hence many anaphylaxis management
plans specify keeping patients supine during
treatment and observation). Its prominence in
Australian insect fatalities are likely related to stings
in remote (often rural/farm settings), where trans-
portation to medical assistance is often not by
ambulance in the first instance.DRUG/IATROGENIC CAUSES
Defining the epidemiology of severe anaphylaxis for
this group of triggers is particularly challenging
because of underrecognition, limited reporting,
and possible concerns as to medicolegal con-
sequences. The majority of anaphylactic reactions
because of iatrogenic causes occur in older age
groups [24,26,28
&
,47], often in patients with comor-
bidities such as coronary artery disease, obesity, and
chronic obstructive airways disease [28
&
]. Whether
this is because of reverse causality is unknown; in a
large series of anaphylaxis presenting to emergency
departments, cardiovascular disease (and use of anti-
hypertensives) was significantly associated with
age but conferred no additional predictive value
for severe reactions on logistic regression analysis
[48
&
]. A similar age distribution is reported for Korea
[49] and the United Kingdom. Hospital admissions
for drug-induced anaphylaxis increased from 0.78 to
1.4 per 100000 population per annum over the
period 1992–2012, predominantly in the 60þ age
group. The mean age of fatal cases because of drugs/
iatrogenic causes was 58 years (95% confidence
interval, 56–61 years), with fatalities rare in those
under 40 [25
&
]. In the United States, fatal
drug-induced anaphylaxis was significantly more
common in African-Americans [27
&
].
The literature indicates that antibiotics (particu-
larly b-lactams) and muscle relaxants are the
primary identified causes ofmedication-related fatal
anaphylaxis (Fig. 1) [50]. NSAIDs appear to be com-
mon triggers for all-cause and severe anaphylaxis,
but less so for fatal anaphylaxis. Thismay be because
of a different route of exposure, with NSAIDs
commonly taken via the oral route. In a cohort from
Korea, drug-induced anaphylaxis was independ-
ently associated with more severe anaphylaxis than
other causes [49], a finding seen elsewhere [51]. This
is often assumed to be because of a parenteral route
of exposure; however, in a prospective Australian
cohort of 315 cases of anaphylaxis presenting to the
emergency department, both injected and oral
drugs (predominantly antibiotics) were strongly pre-
dictive for hypotensive reactions [48
&
].
It is possible that many medication-related ana-
phylaxis hospitalizations and fatalities are coded asHealth, Inc. All rights reserved.
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FIGURE 1. Triggering agents for medication-induced anaphylaxis from series of fatal reactions (a) and anaphylaxis registries
(nonfatal reactions) (b). Reproduced with permission from [50].
Epidemiology of severe anaphylaxis Turner and Campbell‘unspecified cause’ in registries (from all regions),
resulting in significant underreporting. This again
highlights the need for a coordinated approach to
the collection of high-quality accurate data to
inform prescribing practice and identify risk factors
so as to mitigate against serious allergic reactions
and deaths.
Contrast agents are an important cause of ana-
phylaxis. Palmiere and Reggiani Bonetti [52]
reviewed 34 fatalities because of contrast reported
in the literature and a further eight cases in their
own hospital network. Postmortem findings were
nonspecific but consistent with an IgE-mediated
mechanism. Of note, the vast majority of cases
had their fatal event following a first exposure to
the contrast agent; thus, the mechanism of primary
sensitization remains unknown.MAST CELL TRYPTASE AS A BIOMARKER
FOR ANAPHYLAXIS
There is currently no reliable sensitive and specific
biomarker for anaphylaxis or for risk of anaphylaxis.
Anaphylaxis has been assumed to be largely mast
cell or basophil mediated, usually involving an IgE-
mediated mechanism, and although an elevated
mast cell tryptase (MCT) is the most well known
and used biomarker of recent anaphylaxis, it has
poor sensitivity. Moreover, the value of MCT in
attributing anaphylaxis, as the cause of death, is
hindered by a lack of specificity in elevation of Copyright © 2016 Wolters Kluwe
1528-4050 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseMCT postmortem [53]. Individuals with a raised
baseline MCT are known to be at increased risk
for severe reactions to venom [54,55]; in a retro-
spective analysis in patients attending an allergy
clinic in Spain, Fellinger et al. [56] reported a similar
finding for other causes of anaphylaxis, although
fewer than two-thirds of cases were because of
insect stings. Whether a raised baseline MCT is an
independent risk factor for anaphylaxis because of
drugs is therefore unclear. Although Sahiner et al.
[57] proposed that baseline MCT is of value in
predicting severity of reactions in a small cohort
of food-allergic children, the significant overlap
between baseline MCT levels limits the conclusions
which can be made.LEARNING FROM EPIDEMIOLOGY?
It is noteworthy that in series of fatal anaphylaxis
from the United Kingdom [25
&
], the United States
[27
&
], and Australia [28
&
], the age distribution varies
significantly according to the eliciting agent. This
raises important questions about differences in the
pathogenesis of anaphylaxis between different
triggers. The symptoms of anaphylaxis also vary
according to trigger in fatal [20], severe (with hypo-
xemia and/or hypotension) [48
&
], and nonfatal reac-
tions [58]. Although cardiovascular compromise is
common in severe reactions to drugs and insect
venom [48
&
,58], this is uncommon in food-triggered
reactions, where life-threatening manifestations arer Health, Inc. All rights reserved.
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Table 4. Differences in the epidemiology and pathophysiology of anaphylaxis because of food versus nonfood causes
Food
Medication/iatrogenic
causes
Venom
sting
Age distribution:
anaphylaxis (all severity)
Most common in preschool
children, less common
in older adults
Predominantly
older ages
All ages
Age distribution:
fatal anaphylaxis
Young adults into fourth
decade of life.
Rare in younger children
Unusual until fifth
decade of life
Fourth to sixth decade
Symptoms Respiratory Cardiovascular (respiratory
less common)
Cardiovascular (respiratory less common)
Asthma/atopy Common Uncommon Uncommon
Onset Less rapid Rapid Rapid
Site of antigen
presentation
Usually orogastric
route
Usually parenteral
route
Parenteral
Triggering threshold dose þþ Interperson variability
(up to 4 log)
Poor data for
medications
Less variability for insect stings
Mechanism No or relatively modest
increases in MCT
generally observed
Increased MCT
often seen
Increased MCT often seen
Sex M¼ F M¼ F M>>F
Ethnic distribution Possible higher risk in persons
of Asian decent
My be more common in
male children of African
American decent
More common in
persons of
African-American
decent
More common in Caucasians
MCT, mast cell tryptase.
Genetics and epidemiologygenerally because of laryngopharyngeal and/or
respiratory compromise; where cardiovascular arrest
occurs, this is generally secondary to respiratory
arrest [20]. Children with food-related anaphylaxis
tend to present with respiratory and not cardiovas-
cular symptoms [59]; this may give rise to delays in
the use of epinephrine in those presenting with
anaphylaxis [60].
On one level, the differences in symptoms with
differing triggers might be predicted given the
routes of exposure; parenteral allergens (e.g. venom,
nonoral medication) result in rapidly systemic
exposure, and therefore might be expected to cause
cardiovascular involvement more than food aller-
gens which need to be absorbed across the orogas-
trointestinal mucosa. However, this explanation
may be too simplistic. Food allergens such as peanut
can be rapidly absorbed through the buccal mucosa
resulting in plasma levels sufficient to trigger a
systemic effector cell response [61]. Furthermore,
there is some evidence to suggest that severe allergic
reactions to oral medication (such as antibiotics)
frequently cause cardiovascular manifestations –
in common with parentally administered medi-
cation in terms of symptoms elicited – rather than Copyright © 2016 Wolters Kluwer 
448 www.co-allergy.comrespiratory involvement seen with food-triggered
anaphylaxis, despite the fact that gastrointestinal
absorption is still required [48
&
]. The epidemiolog-
ical data therefore raise the possibility that
food-induced anaphylaxis might not have the same
pathophysiologic basis as anaphylaxis caused
by other triggers (Table 4). In this context, it is
interesting to note that MCT is often ‘not’ increased
in severe/fatal food-induced anaphylaxis [62,63],
and when observed, the increase is generally more
modest than that seen in severe anaphylaxis because
of other, nonfood triggers [48
&
,63]. Evaluating
this prospectively through mechanistic assessments
might lead to important advances in our under-
standing of determinants of severity in food-allergic
individuals.CONCLUSION
Anaphylaxis is not uncommon and appears to
be increasing in North American, the United King-
dom, and Australia. Fatal anaphylaxis remains a
rare occurrence, but the fear of such a reaction,
particularly to food triggers, is widespread. Lack of
universal definitions, underreporting, miscoding,Health, Inc. All rights reserved.
Volume 16  Number 5  October 2016
Epidemiology of severe anaphylaxis Turner and Campbellmisdiagnosis, and lack of robust national data
collecting systems hinder the interpretation of
current data. Our current lack of knowledge about
the mechanisms of anaphylaxis further impairs our
capacity to understand why different allergic trig-
gers are associated with different presentations, risk
factors, and age/sex susceptibilities.
Given the worldwide trends for increasing rates
of anaphylaxis to food and medication, there are
significant implications for future fatality trends
with an ageing population accumulating comorbid-
ities such as cardiovascular disease and diabetes.
An improved ability to accurately gather and
analyse population-level anaphylaxis and fatal
anaphylaxis data in a harmonized fashion is
required so as to ultimately improve risk assessment
and management.
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